Our Company

DRAXIMAGE develops, manufactures and markets innovative diagnostic imaging radiopharmaceutical solutions.

We are a major supplier of lyophilized radiopharmaceutical kits for use with Technetium-99m including DRAXIMAGE^® MAA, MDP, DTPA and Glucoheptonate.  DRAXIMAGE^® kits and radiopharmaceuticals are exported worldwide, with regulatory approval in USA, Canada, parts of Europe and South East Asia.  With the introduction of it's Kit for the Preparation of Sodium Iodide I 131 Capsules and Solution USP, Therapeutic Oral in the USA in 2003, DRAXIMAGE has established itself as one of the leading suppliers of I 131 products in North America.

DRAXIMAGE’s vision is to be a global partner of choice in delivering innovative imaging and radiopharmaceutical solutions.

Latest Developments

Jan. 2006 DRAXIMAGE has received approval from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application for Sodium Iodide I-131 Capsules USP, Diagnostic – Oral. These diagnostic sodium iodide I-131 capsules are intended to be used by physicians to perform the radioactive iodide (RAI) uptake test to evaluate thyroid uptake.

Nov. 2005 DRAXIMAGE launched in the U.S.A. a new larger format of its successful Kit for the Preparation of Sodium Iodide I 131 Capsules and Solution USP-Therapeutic-Oral.